These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 25442375)
21. JNK signalling in cancer: in need of new, smarter therapeutic targets. Bubici C; Papa S Br J Pharmacol; 2014 Jan; 171(1):24-37. PubMed ID: 24117156 [TBL] [Abstract][Full Text] [Related]
24. Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. Waetzig V; Herdegen T Trends Pharmacol Sci; 2005 Sep; 26(9):455-61. PubMed ID: 16054242 [TBL] [Abstract][Full Text] [Related]
25. Selective inhibitors for JNK signalling: a potential targeted therapy in cancer. Wu Q; Wu W; Jacevic V; Franca TCC; Wang X; Kuca K J Enzyme Inhib Med Chem; 2020 Dec; 35(1):574-583. PubMed ID: 31994958 [TBL] [Abstract][Full Text] [Related]
26. Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. Tsuiki H; Tnani M; Okamoto I; Kenyon LC; Emlet DR; Holgado-Madruga M; Lanham IS; Joynes CJ; Vo KT; Wong AJ Cancer Res; 2003 Jan; 63(1):250-5. PubMed ID: 12517805 [TBL] [Abstract][Full Text] [Related]
27. Update on JNK inhibitor patents: 2015 to present. Feng G; Yang X; Shuai W; Wang G; Ouyang L Expert Opin Ther Pat; 2024 Oct; 34(10):907-927. PubMed ID: 39223788 [TBL] [Abstract][Full Text] [Related]
28. Recent Advances in c-Jun N-Terminal Kinase (JNK) Inhibitors. Li G; Qi W; Li X; Zhao J; Luo M; Chen J Curr Med Chem; 2021; 28(3):607-627. PubMed ID: 32039671 [TBL] [Abstract][Full Text] [Related]
29. 4-Aryl-1,3,2-oxathiazolylium-5-olate: a novel GST inhibitor to release JNK and activate c-Jun for cancer therapy. Cui H; Shen J; Lu D; Zhang T; Zhang W; Sun D; Wang PG Cancer Chemother Pharmacol; 2008 Aug; 62(3):509-15. PubMed ID: 18008069 [TBL] [Abstract][Full Text] [Related]
30. Synthesis and SAR of 4-substituted-2-aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors. Humphries PS; Lafontaine JA; Agree CS; Alexander D; Chen P; Do QQ; Li LY; Lunney EA; Rajapakse RJ; Siegel K; Timofeevski SL; Wang T; Wilhite DM Bioorg Med Chem Lett; 2009 Apr; 19(8):2099-102. PubMed ID: 19327989 [TBL] [Abstract][Full Text] [Related]
31. Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors. Zhao H; Serby MD; Xin Z; Szczepankiewicz BG; Liu M; Kosogof C; Liu B; Nelson LT; Johnson EF; Wang S; Pederson T; Gum RJ; Clampit JE; Haasch DL; Abad-Zapatero C; Fry EH; Rondinone C; Trevillyan JM; Sham HL; Liu G J Med Chem; 2006 Jul; 49(15):4455-8. PubMed ID: 16854050 [TBL] [Abstract][Full Text] [Related]
32. Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors. Alam M; Beevers RE; Ceska T; Davenport RJ; Dickson KM; Fortunato M; Gowers L; Haughan AF; James LA; Jones MW; Kinsella N; Lowe C; Meissner JW; Nicolas AL; Perry BG; Phillips DJ; Pitt WR; Platt A; Ratcliffe AJ; Sharpe A; Tait LJ Bioorg Med Chem Lett; 2007 Jun; 17(12):3463-7. PubMed ID: 17459703 [TBL] [Abstract][Full Text] [Related]
33. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814 [TBL] [Abstract][Full Text] [Related]
34. Design and characterization of a potent and selective dual ATP- and substrate-competitive subnanomolar bidentate c-Jun N-terminal kinase (JNK) inhibitor. Stebbins JL; De SK; Pavlickova P; Chen V; Machleidt T; Chen LH; Kuntzen C; Kitada S; Karin M; Pellecchia M J Med Chem; 2011 Sep; 54(18):6206-14. PubMed ID: 21815634 [TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK. Hom RK; Bowers S; Sealy JM; Truong AP; Probst GD; Neitzel ML; Neitz RJ; Fang L; Brogley L; Wu J; Konradi AW; Sham HL; Tóth G; Pan H; Yao N; Artis DR; Quinn K; Sauer JM; Powell K; Ren Z; Bard F; Yednock TA; Griswold-Prenner I Bioorg Med Chem Lett; 2010 Dec; 20(24):7303-7. PubMed ID: 21071223 [TBL] [Abstract][Full Text] [Related]
36. Inhibitors of c-jun-N-terminal kinase (JNK). LoGrasso P; Kamenecka T Mini Rev Med Chem; 2008 Jul; 8(8):755-66. PubMed ID: 18673131 [TBL] [Abstract][Full Text] [Related]
37. Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment. Busquets O; Ettcheto M; Cano A; R Manzine P; Sánchez-Lopez E; Espinosa-Jiménez T; Verdaguer E; Dario Castro-Torres R; Beas-Zarate C; X Sureda F; Olloquequi J; Auladell C; Folch J; Camins A Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905931 [TBL] [Abstract][Full Text] [Related]
38. Selective targeting of MAPK family kinases JNK over p38 by rationally designed peptides as potential therapeutics for neurological disorders and epilepsy. Zhuo ZH; Sun YZ; Jin PN; Li FY; Zhang YL; Wang HL Mol Biosyst; 2016 Jul; 12(8):2532-40. PubMed ID: 27263470 [TBL] [Abstract][Full Text] [Related]